Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

Antzeko izenburuak

• The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
  nork: Xiaoxia Wu, et al.
  Argitaratua: (2024-09-01)
• Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
  nork: Jung Min Lee, et al.
  Argitaratua: (2025-01-01)
• A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
  nork: Zhen-Yu Xiong, et al.
  Argitaratua: (2024-12-01)
• Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients
  nork: Xinwen Jiang, et al.
  Argitaratua: (2025-10-01)
• Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia
  nork: Qixing Yang
  Argitaratua: (2026-04-01)